Programmes that monitor local, national and regional levels of transmitted HIV-1 drug resistance inform treatment guidelines and provide feedback on the success of HIV-1 treatment and prevention programmes. The World Health Organization (WHO) has established a global programme for genotypic surveillance of HIV-1 drug resistance and has recommended the adoption of a consensus definition of genotypic drug resistance. Such a definition is necessary to accurately compare transmitted drug resistance rates across geographical regions and time periods. HIV-1 diversity and the large number of mutations associated with antiretroviral drug resistance complicate the development of a consensus definition for genotypic drug resistance. This paper reviews the data that must be considered to determine which of the many HIV-1 drug resistance mutations are likely to be both sensitive and specific indicators of transmitted drug resistance. The process used to create a previously published list of drug resistance mutations for HIV-1 surveillance is reviewed and alternative approaches to this process are discussed.
References
1.
BennettD.E.The requirement for surveillance of HIV drug resistance within antiretroviral rollout in the developing world.Curr Opin Infect Dis2006; 19: 607–614.
2.
BennettD.E., MyattM., BertagnolioS., SutherlandD., GilksC.F.Recommendations for surveillance of transmitted HIV drug resistance in countries scaling up antiretroviral treatment.Antivir Ther2008; 13Suppl 2: 25–36.
3.
PillayD.Current patterns in the epidemiology of primary HIV drug resistance in North America and Europe.Antivir Ther2004; 9: 695–702.
4.
GerettiA.M.Epidemiology of antiretroviral drug resistance in drug naive persons.Curr Opin Infect Dis2007; 20: 22–32.
5.
ShaferR.W., RheeS.Y., PillayD.HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance.AIDS2007; 21: 215–223.
6.
ParkinN.T., HellmannN.S., WhitcombJ.M., KissL., ChappeyC., PetropoulosC.J.Natural variation of drug susceptibility in wild-type HIV-1.Antimicrob Agents Chemother2004; 48: 437–443.
7.
ZhangJ., RheeS.Y., TaylorJ., ShaferR.W.Comparison of the precision and sensitivity of the Antivirogram and PhenoSense HIV drug susceptibility assays.J Acquir Immune Defic Syndr2005; 38: 439–444.
8.
SchuurmanR., DemeterL., ReichelderferP., TijnagelJ., de GrootT., BoucherC.Worldwide evaluation of DNA sequencing approaches for identification of drug resistance mutations in the human immunodeficiency virus type 1 reverse transcriptase.J Clin Microbiol1999; 37: 2291–2296.
9.
SchuurmanR., BrambillaD., de GrootT.Underestimation of HIV type 1 drug resistance mutations: results from the ENVA-2 genotyping proficiency program.AIDS Res Hum Retroviruses2002; 18: 243–248.
10.
ShaferR.W., HertogsK., ZolopaA.R.High degree of interlaboratory reproducibility of human immunodeficiency virus type 1 protease and reverse transcriptase sequencing of plasma samples from heavily treated patients.J Clin Microbiol2001; 39: 1522–1529.
11.
KornK., ReilH., WalterH., SchmidtB.Quality control trial for human immunodeficiency virus type 1 drug resistance testing using clinical samples reveals problems with detecting minority species and interpretation of test results.J Clin Microbiol2003; 41: 3559–3565.
12.
GrantR.M., KuritzkesD.R., JohnsonV.A.Accuracy of the TRUGENE HIV-1 genotyping kit.J Clin Microbiol2003; 41: 1586–1593.
13.
EshlemanS.H., HackettJ.Jr., SwansonP.Performance of the Celera Diagnostics ViroSeq HIV-1 Genotyping System for sequence-based analysis of diverse human immunodeficiency virus type 1 strains.J Clin Microbiol2004; 42: 2711–2717.
YerlyS., RakikA., De LoesS.K.Switch to unusual amino acids at codon 215 of the human immunodeficiency virus type 1 reverse transcriptase gene in seroconvertors infected with zidovudine-resistant variants.J Virol1998; 72: 3520–3523.
16.
Garcia-LermaJ.G., NidthaS., BlumoffK., WeinstockH., HeneineW.Increased ability for selection of zidovudine resistance in a distinct class of wild-type HIV-1 from drug naive persons.Proc Natl Acad Sci U S A2001; 98: 13907–13912.
17.
LittleS., DawsonK., HellmannN., RichmanD.D., FrostS.Persistence of transmitted drug–resistant virus among subjects with primary HIV infection deferring antiretroviral therapy.Antivir Ther2003; 8: S129.
18.
GandhiR.T., WurcelA., RosenbergE.S.Progressive reversion of human immunodeficiency virus type 1 resistance mutations in vivo after transmission of a multiply drug resistant virus.Clin Infect Dis2003; 37: 1693–1698.
19.
WhitcombJ.M., ParkinN.T., ChappeyC., HellmannN.S., PetropoulosC.J.Broad nucleoside reverse-transcriptase inhibitor cross-resistance in human immunodeficiency virus type 1 clinical isolates.J Infect Dis2003; 188: 992–1000.
20.
WhitcombJ.M., HuangW., LimoliK.Hypersusceptibility to non-nucleoside reverse transcriptase inhibitors in HIV-1: clinical, phenotypic and genotypic correlates.AIDS2002; 16: F41–47.
RheeS.Y., FesselW.J., ZolopaA.R.HIV-1 protease and reverse-transcriptase mutations: correlations with antiretroviral therapy in subtype B isolates and implications for drug resistance surveillance.J Infect Dis2005; 192: 456–465.
23.
ClarkS., CalefC., MellorsJ.W.Mutations in retroviral genes associated with drug resistance. In HIV Sequence Compendium2006/2007. Edited by: LeitnerT., FoleyB., HahnB.Los Alamos, NM, USA: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory; 2007. LA-UR 07-4826. pp. 58–158.
24.
PernoC.F., SvicherV., Ceccherini-SilbersteinF.Novel drug resistance mutations in HIV: recognition and clinical relevance.AIDS Rev2006; 8: 179–190.
25.
Van LaethemK., De LucaA., AntinoriA., CingolaniA., PernaC.F., VandammeA.M.A genotypic drug resistance interpretation algorithm that significantly predicts therapy response in HIV-1-infected patients.Antivir Ther2002; 7: 123–129.
JohnsonV.A., Brun-VezinetF., ClotetB.Update of the Drug Resistance Mutations in HIV-1: 2005.Top HIV Med2005; 13: 51–57.
28.
DescampsD., ChaixM.L., AndreP.French national sentinel survey of antiretroviral drug resistance in patients with HIV-1 primary infection and in antiretroviral-naive chronically infected patients in 2001–2002.J Acquir Immune Defic Syndr2005; 38: 545–552.
29.
CamachoR., GodinhoA., GomesP.Different substitutions under drug pressure at protease codon 82 in HIV–1 subtype G compared to subtype B infected individuals including a novel I82M resistance mutations.Antivir Ther2005; 10: S151.
30.
MohriH., SinghM.K., ChingW.T., HoD.D.Quantitation of zidovudine-resistant human immunodeficiency virus type 1 in the blood of treated and untreated patients.Proc Natl Acad Sci U S A1993; 90: 25–29.
31.
AlbertJ., WahlbergJ., LeitnerT., EscanillaD., UhlenM.Analysis of a rape case by direct sequencing of the human immunodeficiency virus type 1 pol and gag genes.J Virol1994; 68: 5918–5924.
32.
De MeyerS., VangeneugdenT., LefebvreE.Phenotypic and genotypic determination of resistance to TMC114: pooled analysis of POWER 1, 2, and 3.Antivir Ther2006; 11: S83.
33.
AbecasisA.B., DeforcheK., SnoeckJ.Protease mutation M89I/V is linked to therapy failure in patients infected with the HIV-1 non-B subtypes C, F or G.AIDS2005; 19: 1799–1806.
34.
KantorR., KatzensteinD.A., EfronB.Impact of HIV–1 subtype and antiretroviral therapy on protease and reverse transcriptase genotype: results of a global collaboration.PLoS Med2005; 2: e112.
35.
BrennerB., TurnerD., OliveiraM.A V106M mutation in HIV-1 clade C viruses exposed to efavirenz confers cross-resistance to non-nucleoside reverse transcriptase inhibitors.AIDS2003; 17: F1–F5.
36.
GrossmanZ., IstominV., AverbuchD.Genetic variation at NNRTI resistance-associated positions in patients infected with HIV-1 subtype C.AIDS2004; 18: 909–915.
37.
CaneP.A., de RuiterA., RiceP., WiselkaM., FoxR., PillayD.Resistance-associated mutations in the human immunodeficiency virus type 1 subtype c protease gene from treated and untreated patients in the United Kingdom.J Clin Microbiol2001; 39: 2652–2654.
38.
SugiuraW., MatsudaZ., YokomakuY.Interference between D30N and L90M in selection and development of protease inhibitor-resistant human immunodeficiency virus type 1.Antimicrob Agents Chemother2002; 46: 708–715.
39.
GrossmanZ., PaxinosE.E., AverbuchD.Mutation D30N is not preferentially selected by human immunodeficiency virus type 1 subtype C in the development of resistance to nelfinavir.Antimicrob Agents Chemother2004; 48: 2159–2165.
40.
CalazansA., BrindeiroR., BrindeiroP.Low accumulation of L90M in protease from subtype F HIV-1 with resistance to protease inhibitors is caused by the L89M polymorphism.J Infect Dis2005; 191: 1961–1970.
41.
GiffordR., de OliveiraT., RambautA.Assessment of automated genotyping protocols as tools for surveillance of HIV-1 genetic diversity.AIDS2006; 20: 1521–1529.
42.
LindstromA., OhlisA., HuigenM.HIV-1 transmission cluster with M41L ‘singleton’ mutation and decreased transmission of resistance in newly diagnosed Swedish homosexual men.Antivir Ther2006; 11: 1031–1039.
43.
CarrJ.K., NadaiY., EyzaguirreL.Outbreak of a West African recombinant of HIV–1 in Tashkent, Uzbekistan.J Acquir Immune Defic Syndr2005; 39: 570–575.
